Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qijian mixture
- Development stage
- Preclinical
- Lead developer
- Beijing University of Chinese Medicine
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Qijian mixture is a traditional Chinese medicine (TCM) formula comprising *Astragalus membranaceus*, *Ramulus euonymi*, *Coptis chinensis*, and *Pueraria lobata*, developed for the treatment of type 2 diabetes (T2D). The formula exerts its therapeutic effects through a multi-target approach, including the modulation of gut microbiota (specifically enriching the Bacteroidetes phylum) and the regulation of metabolic pathways such as galactose metabolism and amino acid degradation. System pharmacology analysis indicates that Qijian mixture acts via key signaling proteins, including AKT1, PPARA, and TP53. Preclinical studies in diabetic mouse models have demonstrated its efficacy in lowering blood glucose levels and its safety profile, showing a similar hypoglycemic trend to metformin.
- Other names
- Qijian Mixture
02
Targets
AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)PPARA (Peroxisome proliferator-activated receptor alpha)TP53 (Cellular Tumor Antigen p53 R175H)AKT (RAC-alpha serine/threonine-protein kinase)
Beyond the preview
Go deeper on Qijian mixture.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Qijian mixture.